Study objectives
PD
The primary objective of this study was to assess the safety and tolerability of inclacumab after a single dose at different dose levels in healthy participants. Secondary objectives were to characterize the plasma PK of inclacumab and the effect of inclacumab on PD in healthy participants. Characterizing the anti-drug antibody (ADA) response to inclacumab and the effects of inclacumab on other biomarkers in healthy participants, as well as exploring the relationships between PK, PD, ADA, and safety, were exploratory objectives.